Article Information
vol. 31 no. 164
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 2, 2022
- Accepted April 4, 2022
- Published online June 7, 2022.
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Alberto L. Garcia-Basteiro1,2,3⇑,
- Richard G. White4,
- Dereck Tait5,
- Alexander C. Schmidt6,
- Molebogeng X. Rangaka7,8,
- Matthew Quaife4,
- Elisa Nemes9,
- Robin Mogg10,
- Philip C. Hill11,
- Rebecca C. Harris4,12,
- Willem A. Hanekom13,14,
- Mike Frick15,
- Andrew Fiore-Gartland16,
- Tom Evans17,
- Alemnew F. Dagnew6,
- Gavin Churchyard18,19,20,
- Frank Cobelens21,
- Marcel A. Behr22 and
- Mark Hatherill9
- 1Centro de Investigação em Sade de Manhiça (CISM), Maputo, Mozambique
- 2ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
- 3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECT), Barcelona, Spain
- 4London School of Hygiene and Tropical Medicine, London, UK
- 5International AIDS Vaccine Initiative (IAVI) NPC, Cape Town, South Africa
- 6Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA
- 7Institute for Global Health and MRC Clinical Trials Unit at University College London, London, UK
- 8CIDRI-AFRICA, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
- 9South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Dept of Pathology, University of Cape Town, Cape Town, South Africa
- 10Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
- 11Centre for International Health, University of Otago, Dunedin, New Zealand
- 12Sanofi Pasteur, Singapore
- 13Africa Health Research Institute, KwaZulu-Natal, South Africa
- 14Division of Infection and Immunity, University College London, London, UK
- 15Treatment Action Group, New York, NY, USA
- 16Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 17Vaccitech, Oxford, UK
- 18The Aurum Institute, Parktown, South Africa
- 19Vanderbilt University, Nashville, TN, USA
- 20University of the Witwatersrand, Johannesburg, South Africa
- 21Dept of Global Health and Amsterdam Institute for Global health and development, Amsterdam University Medical Centres, Amsterdam, The Netherlands
- 22Dept of Medicine, McGill University; McGill International TB Centre, Montreal, QC, Canada
- Corresponding author: Alberto L. Garcia-Basteiro (alberto.garcia-basteiro{at}manhica.net)
Article usage
Altmetrics
Vol 31 Issue 164
Table of Contents
End-point definition and trial design to advance tuberculosis vaccine development
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Prevention of infection (POI) approaches to accelerate candidate vaccines into prevention of disease (POD) efficacy trials
- Optimising TB disease end-points for future efficacy trials
- End-point definition in vaccine trials including PLHIV
- Conclusions
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics